The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cholangiocarcinoma


High impact information on Cholangiocarcinoma


Chemical compound and disease context of Cholangiocarcinoma


Biological context of Cholangiocarcinoma


Anatomical context of Cholangiocarcinoma


Gene context of Cholangiocarcinoma


Analytical, diagnostic and therapeutic context of Cholangiocarcinoma


  1. Effects of phenobarbital and secondary bile acids on liver, gallbladder, and pancreas carcinogenesis initiated by N-nitrosobis (2-hydroxypropyl)amine in hamsters. Makino, T., Obara, T., Ura, H., Kinugasa, T., Kobayashi, H., Takahashi, S., Konishi, Y. J. Natl. Cancer Inst. (1986) [Pubmed]
  2. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. Caussanel, J.P., Lévi, F., Brienza, S., Misset, J.L., Itzhaki, M., Adam, R., Milano, G., Hecquet, B., Mathé, G. J. Natl. Cancer Inst. (1990) [Pubmed]
  3. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Olsson, R., Boberg, K.M., de Muckadell, O.S., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy-Kristiansen, M., Matre, J., Rydning, A., Wikman, O., Danielsson, A., Sandberg-Gertzén, H., Ung, K.A., Eriksson, A., Lööf, L., Prytz, H., Marschall, H.U., Broomé, U. Gastroenterology (2005) [Pubmed]
  4. Ultrasonic Doppler studies of hepatocellular carcinoma and comparison with other hepatic focal lesions. Ohnishi, K., Nomura, F. Gastroenterology (1989) [Pubmed]
  5. Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. Lavaissiere, L., Jia, S., Nishiyama, M., de la Monte, S., Stern, A.M., Wands, J.R., Friedman, P.A. J. Clin. Invest. (1996) [Pubmed]
  6. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Ishimura, N., Bronk, S.F., Gores, G.J. Gastroenterology (2005) [Pubmed]
  7. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Yoon, J.H., Higuchi, H., Werneburg, N.W., Kaufmann, S.H., Gores, G.J. Gastroenterology (2002) [Pubmed]
  8. Photodynamic therapy of nonresectable cholangiocarcinoma. Ortner, M.A., Liebetruth, J., Schreiber, S., Hanft, M., Wruck, U., Fusco, V., Müller, J.M., Hörtnagl, H., Lochs, H. Gastroenterology (1998) [Pubmed]
  9. Iridium-192 wire for hilar cholangiocarcinoma. Benjamin, I.S., McPherson, G.A., Blumgart, L.H. Lancet (1981) [Pubmed]
  10. Ursodeoxycholate increases cytosolic calcium concentration and activates Cl- currents in a biliary cell line. Shimokura, G.H., McGill, J.M., Schlenker, T., Fitz, J.G. Gastroenterology (1995) [Pubmed]
  11. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Han, C., Leng, J., Demetris, A.J., Wu, T. Cancer Res. (2004) [Pubmed]
  12. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. Lempinen, M., Isoniemi, H., Mäkisalo, H., Nordin, A., Halme, L., Arola, J., Höckerstedt, K., Stenman, U.H. J. Hepatol. (2007) [Pubmed]
  13. Hepatocytic phenotypes induced in sarcomatous cholangiocarcinoma cells treated with 5-azacytidine. Enjoji, M., Nakashima, M., Honda, M., Sakai, H., Nawata, H. Hepatology (1997) [Pubmed]
  14. Ezrin-radixin-moesin-binding phosphoprotein 50 is expressed at the apical membrane of rat liver epithelia. Fouassier, L., Duan, C.Y., Feranchak, A.P., Yun, C.H., Sutherland, E., Simon, F., Fitz, J.G., Doctor, R.B. Hepatology (2001) [Pubmed]
  15. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Levi, S., Urbano-Ispizua, A., Gill, R., Thomas, D.M., Gilbertson, J., Foster, C., Marshall, C.J. Cancer Res. (1991) [Pubmed]
  16. Cell proliferation and oncogene expression after bile duct ligation in the rat: evidence of a specific growth effect on bile duct cells. Polimeno, L., Azzarone, A., Zeng, Q.H., Panella, C., Subbotin, V., Carr, B., Bouzahzah, B., Francavilla, A., Starzl, T.E. Hepatology (1995) [Pubmed]
  17. Low frequency of p53 gene mutation in tumors induced by aflatoxin B1 in nonhuman primates. Fujimoto, Y., Hampton, L.L., Luo, L.D., Wirth, P.J., Thorgeirsson, S.S. Cancer Res. (1992) [Pubmed]
  18. Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies. Ponder, K.P. FASEB J. (1996) [Pubmed]
  19. Carcinoembryonic antigen and blood group-related carbohydrate antigens in glycoproteins in human bile in hepatolithiasis. Japanese Study Group of Hepatolithiasis. Sasaki, M., Morita, T., Hoso, M., Nakanuma, Y., Tanimura, H. Hepatology (1996) [Pubmed]
  20. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Higashi, M., Yonezawa, S., Ho, J.J., Tanaka, S., Irimura, T., Kim, Y.S., Sato, E. Hepatology (1999) [Pubmed]
  21. Effect of cholecystokinin on human cholangiocarcinoma xenografted into nude mice. Hudd, C., Euhus, D.M., LaRegina, M.C., Herbold, D.R., Palmer, D.C., Johnson, F.E. Cancer Res. (1985) [Pubmed]
  22. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Tan, C.K., Podila, P.V., Taylor, J.E., Nagorney, D.M., Wiseman, G.A., Gores, G.J., LaRusso, N.F. Gastroenterology (1995) [Pubmed]
  23. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. Han, C., Demetris, A.J., Michalopoulos, G.K., Zhan, Q., Shelhamer, J.H., Wu, T. Hepatology (2003) [Pubmed]
  24. Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. Wu, T., Han, C., Lunz, J.G., Michalopoulos, G., Shelhamer, J.H., Demetris, A.J. Hepatology (2002) [Pubmed]
  25. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Park, J., Tadlock, L., Gores, G.J., Patel, T. Hepatology (1999) [Pubmed]
  26. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Ashida, K., Terada, T., Kitamura, Y., Kaibara, N. Hepatology (1998) [Pubmed]
  27. Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver. Lai, G.H., Radaeva, S., Nakamura, T., Sirica, A.E. Hepatology (2000) [Pubmed]
  28. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Kluge, R., Schmidt, F., Caca, K., Barthel, H., Hesse, S., Georgi, P., Seese, A., Huster, D., Berr, F. Hepatology (2001) [Pubmed]
  29. Cholangiocarcinomas induced by feeding 3'-methyl-4-dimethylaminoazobenzene to rats. Histopathology and ultrastructure. Reddy, K.P., Buschmann, R.J., Chomet, B. Am. J. Pathol. (1977) [Pubmed]
  30. Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells. Okaro, A.C., Fennell, D.A., Corbo, M., Davidson, B.R., Cotter, F.E. Gut (2002) [Pubmed]
  31. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Goydos, J.S., Brumfield, A.M., Frezza, E., Booth, A., Lotze, M.T., Carty, S.E. Ann. Surg. (1998) [Pubmed]
WikiGenes - Universities